Moniyot-131 T (Sodium Iodide (131i))

Sodium Iodide (I‑131) is taken up by thyroid follicular cells via the sodium‑iodide symporter. Once inside the gland, the radioactive iodine emits beta particles that cause localized cellular damage, and gamma photons that can be detected by a gamma camera. This dual action provides both imaging capability and, at higher doses, therapeutic destruction of overactive thyroid cells.

The dose of Moniyot-131 T is determined individually by the prescribing physician based on the intended diagnostic or therapeutic purpose, the patient’s thyroid status, and regulatory guidelines. Dosage calculations consider the required radioactivity (measured in megabecquerels) and patient-specific factors. Clinicians set the exact amount to ensure optimal imaging quality or therapeutic effect while minimizing radiation exposure.

Radioactive iodine can cross the placenta and enter breast milk, potentially affecting fetal or neonatal thyroid development. Consequently, Moniyot-131 T is generally avoided in pregnant or breastfeeding women unless the clinical benefit clearly outweighs the risk. If use is unavoidable, the prescribing physician will implement strict radiation safety measures and may advise temporary cessation of breastfeeding for a defined period.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity of Moniyot-131 T. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The sales team then confirms pricing, availability, shipping conditions (including any required radiation handling) and assists with import documentation.

Moniyot-131 T delivers iodine‑131, which provides both diagnostic gamma emission and therapeutic beta radiation. Compared with iodine‑123, which emits only gamma photons, I‑131 enables combined imaging and treatment but involves higher radiation dose. Iodine‑131 is also distinct from non‑radioactive antithyroid drugs, offering a targeted ablative approach rather than systemic hormone synthesis inhibition. Choice of agent depends on clinical goals, required radiation dose, and regulatory considerations.

Moniyot-131 T should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. The product must be protected from moisture, light, and physical damage. Because it is a radioactive material, handling should follow local radiation safety regulations, including use of appropriate shielding, labeling, and disposal procedures. Facilities must maintain a secure inventory and limit exposure to personnel and the public.

Moniyot-131 T is administered orally, typically as a single dose in liquid or capsule form, depending on the specific product presentation. The patient swallows the dose with water under the supervision of a qualified healthcare professional. After ingestion, the patient may be instructed to follow radiation safety precautions, such as limiting close contact with others for a prescribed period, to reduce unnecessary radiation exposure.

The most serious risks include radiation‑induced thyroiditis, severe hypothyroidism or exacerbated hyperthyroidism, and bone marrow suppression leading to cytopenias. In rare cases, allergic reactions or anaphylaxis may occur. Long‑term exposure carries a small risk of secondary malignancies due to ionizing radiation. Patients should be monitored closely for signs of these complications, and any adverse symptoms should be reported to the treating physician promptly.

Moniyot-131 T is contraindicated in individuals with known hypersensitivity to iodine or sodium iodide, in pregnant women unless absolutely necessary, and in breastfeeding mothers who cannot suspend nursing. Patients with uncontrolled thyroid disorders that require alternative management, or those who cannot comply with radiation safety guidelines, should also avoid its use. The prescribing clinician must evaluate each patient’s medical history and current condition before deciding on therapy.